TipRanksStock Market NewsMaxim Group Thinks Monopar Therapeutics Inc’s Stock is Going to Recover

Maxim Group Thinks Monopar Therapeutics Inc’s Stock is Going to Recover

Maxim Group analyst Jason McCarthy maintained a Buy rating on Monopar Therapeutics Inc (MNPRResearch Report) on February 2 and set a price target of $8.00. The company’s shares closed last Friday at $2.76, close to its 52-week low of $2.36.

According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics.

Currently, the analyst consensus on Monopar Therapeutics Inc is a Strong Buy with an average price target of $16.67.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $17.01 and a one-year low of $2.36. Currently, Monopar Therapeutics Inc has an average volume of 21.25K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Read More on MNPR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More